Document ID: chunk:federal_register_of_legislation:F2025L00215:schedule:1:p8
Version: federal_register_of_legislation:F2025L00215
Segment Type: schedule
Provision Reference: sch 1 (pt 8/51)
Character Range: 21585–24688

Oral  AKM Fingolimod        RW  MP NP  C16301 C16323     28  5     28
Fingolimod  Capsule 500 micrograms (as hydrochloride)  Oral  Fingolimod Sandoz     SZ  MP NP  C16301 C16323     28  5     28
Fingolimod  Capsule 500 micrograms (as hydrochloride)  Oral  Fingolimod SUN        RA  MP NP  C16301 C16323     28  5     28
Fingolimod  Capsule 500 micrograms (as hydrochloride)  Oral  Fingolimod-Teva       TB  MP NP  C16301 C16323     28  5     28
Fingolimod  Capsule 500 micrograms (as hydrochloride)  Oral  Fynod                 AF  MP NP  C16301 C16323     28  5     28
Fingolimod  Capsule 500 micrograms (as hydrochloride)  Oral  Gilenya               NV  MP NP  C16301 C16323     28  5     28
Fingolimod  Capsule 500 micrograms (as hydrochloride)  Oral  Pharmacor Fingolimod  CR  MP NP  C16301 C16323     28  5     28

[39] Schedule 1, Part 1, entry for Fluoxetine in the form Tablet, dispersible, 20 mg (as hydrochloride)
substitute:
Fluoxetine  Tablet, dispersible, 20 mg (as hydrochloride)  Oral  Zactin Tablet  AF  MP NP  C4755 C6277    P4755 P6277    28  5     28
Fluoxetine  Tablet, dispersible, 20 mg (as hydrochloride)  Oral  Zactin Tablet  AF  MP NP  C15582 C15666  P15582 P15666  56  2     28

[40] Schedule 1, Part 1, entries for Glatiramer
(a) omit from the column headed "Authorised Prescriber" (all instances): MP substitute (all instances): MP NP
(b) omit from the column headed "Circumstances" (all instances): C6860 C7695 substitute (all instances):C16297 C16321
[41] Schedule 1, Part 1, entries for Gliclazide in the form Tablet 30 mg (modified release)
substitute:
Gliclazide  Tablet 30 mg (modified release)  Oral  APO-Gliclazide MR        TX  MP NP             100  5     100
Gliclazide  Tablet 30 mg (modified release)  Oral  APO-Gliclazide MR        TX  MP NP     P14238  200  5     100
Gliclazide  Tablet 30 mg (modified release)  Oral  Gliclazide MR Viatris    AL  MP NP             100  5     100
Gliclazide  Tablet 30 mg (modified release)  Oral  Gliclazide MR Viatris    AL  MP NP     P14238  200  5     100
Gliclazide  Tablet 30 mg (modified release)  Oral  Glyade MR                AF  MP NP             100  5     100
Gliclazide  Tablet 30 mg (modified release)  Oral  Glyade MR                AF  MP NP     P14238  200  5     100
Gliclazide  Tablet 30 mg (modified release)  Oral  Pharmacor Gliclazide MR  CR  MP NP             100  5     100
Gliclazide  Tablet 30 mg (modified release)  Oral  Pharmacor Gliclazide MR  CR  MP NP     P14238  200  5     100

[42] Schedule 1, Part 1, entry for Inclisiran in the form Injection 284 mg in 1.5 mL single use pre-filled syringe [Maximum Quantity: 1; Number of Repeats: 0]
(a) omit from the column headed "Authorised Prescriber": MP substitute: MP NP
(b) omit from the column headed "Circumstances": C15065 C15110 C15338 C15369 substitute: C16312 C16320 C16352 C16356
(c) omit from the column headed "Purposes": P15065 P15110 P15338 P15369 substitute: P16312 P16320 P16352 P16356
[43] Schedule 1, Part 1, entry for Inclisiran in the form Injection 284 mg in 1.5 mL single use pre-filled syringe [Maximum Quantity: 1; Number of